Loading...
Market
Market impact of Transcarent's strategic acquisitions in 2024
5
Resolution / Starting Odds
Significantly positive • 33%
Moderately positive • 34%
No significant change • 33%
Market analysis reports, health tech industry assessments
Story
Transcarent Raises $126M, Valued at $2.2B, Eyes AI Expansion and Acquisitions
May 2, 2024, 03:30 PM
Transcarent, a health tech unicorn co-founded by Glen Tullman, has successfully raised $126 million in a Series D funding round. The round was led by General Catalyst and 7wireVentures. This new influx of capital, which values Transcarent at $2.2 billion, is earmarked for advancing AI projects and strategic acquisitions. The funding signifies a positive shift in the health tech funding landscape, suggesting a market rebound.
View original story
Similar markets
Market position strengthened • 33%
Market position weakened • 33%
Market position remains stable • 34%
Significantly positive • 33%
Neutral • 33%
Negative • 34%
Significant increase • 33%
Moderate increase • 33%
No change or decrease • 34%
Performs better than average • 33%
Performs on par with average • 34%
Underperforms compared to average • 33%
Increase more than 10% • 25%
Increase less than 10% • 25%
Decrease less than 10% • 25%
Decrease more than 10% • 25%
Significant decrease • 33%
Minor impact • 33%
No impact • 34%
Significant Positive Impact • 25%
Moderate Positive Impact • 25%
No Significant Impact • 25%
Negative Impact • 25%
Increase • 33%
Decrease • 33%
No significant change • 34%
Technology • 20%
Financials • 20%
Consumer Goods • 20%
Healthcare • 20%
Energy • 20%
Increase in market share • 33%
No change in market share • 34%
Decrease in market share • 33%
Positive Growth • 33%
Stable, No Significant Change • 34%
Negative Growth • 33%
Partnership formed • 25%
Acquisition by a competitor • 25%
No engagement • 25%
Government intervention • 25%